NASDAQ: ABSIAbsci Corp Stock
$4.10+0.03 (+0.74%)
Updated Oct 14, 2024
ABSI Price
$4.10
Fair Value Price
-$1.65
Market Cap
$465.58M
52 Week Low
$1.11
52 Week High
$6.72
P/E
-4.41x
P/B
2.1x
P/S
107.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.25M
Earnings
-$92.26M
Gross Margin
100%
Operating Margin
-2,812.65%
Profit Margin
-2,838.9%
Debt to Equity
0.15
Operating Cash Flow
-$60M
Beta
2.15
Next Earnings
Nov 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ABSI Overview
Absci Corp. partners offers its Integrated Drug Creation platform that uses synthetic biology technologies and deep learning artificial intelligence to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them, all in a single process. Absci Corp was founded in 2011 and is headquartered in Vancouver, WA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABSI ($4.10) is overvalued by 349.13% relative to our estimate of its Fair Value price of -$1.65 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABSI ($4.10) is not significantly undervalued (349.13%) relative to our estimate of its Fair Value price of -$1.65 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABSI due diligence checks available for Premium users.
Be the first to know about important ABSI news, forecast changes, insider trades & much more!
ABSI News
Valuation
ABSI fair value
Fair Value of ABSI stock based on Discounted Cash Flow (DCF)
Price
$4.10
Fair Value
-$1.65
Undervalued by
349.13%
ABSI ($4.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABSI ($4.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.41x
Industry
-124.07x
Market
27.44x
ABSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.1x
Industry
6.12x
ABSI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABSI's financial health
Profit margin
Revenue
$1.3M
Net Income
-$24.8M
Profit Margin
-1,948.8%
ABSI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ABSI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$255.5M
Liabilities
$34.0M
Debt to equity
0.15
ABSI's short-term assets ($165.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABSI's short-term assets ($165.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.8M
Investing
$1.3M
Financing
-$134.0k
ABSI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABSI vs Biotech Stocks
Absci Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.